{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T05:54:22Z","timestamp":1781589262831,"version":"3.54.5"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>FINEARTS-HF moved finerenone from cardiorenal biological plausibility to randomized outcome evidence for selected adults with symptomatic heart failure (HF) and left ventricular ejection fraction (LVEF) \u226540%. Finerenone reduced the prespecified composite of cardiovascular death and total worsening HF events, with benefit driven mainly by fewer worsening HF events; cardiovascular death as an individual endpoint was not significantly reduced. This focused narrative Review defines the evidence boundaries after FINEARTS-HF and translates them into clinical implementation for cardiovascular-kidney-metabolic (CKM)-burdened HF with LVEF \u226540%. CKM features are used as a practical framework for risk organization, multimorbidity assessment, competing symptom mechanisms, and monitoring intensity, not as diagnostic criteria, eligibility criteria, or validated predictors of relative response. Safe use requires confirmed symptomatic HF, exclusion of mimickers, confirmation of the local prescribing information, baseline potassium and eGFR assessment, HF-specific dosing, interaction review, laboratory reassessment around 4 weeks after initiation and dose changes, and reassessment during acute illness or unstable renal function. Finerenone should complement SGLT2 inhibitors, decongestion, obesity-directed therapy when indicated, atrial fibrillation care, blood-pressure control, exercise, and nutrition. Future studies should quantify absolute benefit across CKM risk, test UACR, biomarker, and imaging mediation, define combination and sequencing strategies, compare safety with steroidal mineralocorticoid receptor antagonists, and evaluate real-world implementation.<\/jats:p>","DOI":"10.3389\/fcvm.2026.1880045","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T05:39:36Z","timestamp":1781588376000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Finerenone after FINEARTS-HF: evidence boundaries and implementation in heart failure with LVEF \u226540%"],"prefix":"10.3389","volume":"13","author":[{"given":"Shihang","family":"Feng","sequence":"first","affiliation":[{"name":"College of Traditional Chinese Medicine, Changchun University of Chinese Medicine","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongguang","family":"Jin","sequence":"additional","affiliation":[{"name":"The Affiliated Hospital to Changchun University of Chinese Medicine","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/ejhf.2115","article-title":"Universal definition and classification of heart failure: a report of the heart failure society of America, heart failure association of the European Society of Cardiology, Japanese heart failure society and writing committee of the universal definition of heart failure: endorsed by the Canadian heart failure society, heart failure association of India, cardiac society of Australia and New Zealand, and Chinese heart failure association","volume":"23","author":"Bozkurt","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/j.jacc.2023.01.049","article-title":"Heart failure with preserved ejection fraction: JACC scientific statement","volume":"81","author":"Borlaug","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1161\/CIRCULATIONAHA.114.010637","article-title":"Phenomapping for novel classification of heart failure with preserved ejection fraction","volume":"131","author":"Shah","year":"2015","journal-title":"Circulation"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-Kidney-Metabolic Health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1002\/ejhf.1902","article-title":"Characterization of the inflammatory-metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease","volume":"22","author":"Packer","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"B7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","article-title":"Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction","volume":"136","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"B8","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jacc.2024.05.005","article-title":"Cardiovascular-Kidney-Metabolic overlap in heart failure with mildly reduced or preserved ejection fraction: a trial-level analysis","volume":"84","author":"Ostrominski","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1002\/ejhf.3304","article-title":"Cardiovascular-kidney-metabolic overlap in heart failure with preserved ejection fraction: cardiac structure and function, clinical outcomes, and response to sacubitril\/valsartan in PARAGON-HF","volume":"26","author":"Lassen","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/j.cjca.2025.07.027","article-title":"Canadian Cardiovascular Society\/Canadian heart failure society 2025 guideline update for pharmacologic management of heart failure with nonreduced ejection fraction (LVEF > 40%)","volume":"41","author":"Virani","year":"2025","journal-title":"Can J Cardiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s10741-024-10462-2","article-title":"A fine addition: finerenone in the evolving landscape of heart failure with preserved ejection fraction","volume":"30","author":"Halaseh","year":"2025","journal-title":"Heart Fail Rev"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"B13","year":""},{"key":"B14","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.2337\/dc22-0294","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: the FIDELITY analysis","volume":"45","author":"Rossing","year":"2022","journal-title":"Diabetes Care"},{"key":"B19","year":""},{"key":"B20","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jacc.2024.10.091","article-title":"Finerenone and kidney outcomes in patients with heart failure: the FINEARTS-HF trial","volume":"85","author":"Causland FR","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"102439","DOI":"10.1016\/j.jchf.2025.03.006","article-title":"Finerenone across the spectrum of kidney risk in heart failure: the FINEARTS-HF trial","volume":"14","author":"Ostrominski","year":"2026","journal-title":"JACC Heart Fail"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1002\/ejhf.3649","article-title":"Finerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the FINEARTS-HF trial","volume":"27","author":"Butt","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"B23","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jacc.2024.10.111","article-title":"Finerenone, obesity, and heart failure with mildly reduced\/preserved ejection fraction: prespecified analysis of FINEARTS-HF","volume":"85","author":"Butt","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1001\/jamacardio.2025.1101","article-title":"Finerenone in heart failure with improved ejection fraction: the FINEARTS-HF randomized clinical trial","volume":"10","author":"Pabon","year":"2025","journal-title":"JAMA Cardiol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"102497","DOI":"10.1016\/j.jchf.2025.03.041","article-title":"Efficacy and safety of finerenone in heart failure with preserved ejection fraction: a FINE-HEART analysis","volume":"13","author":"Ostrominski","year":"2025","journal-title":"JACC Heart Fail"},{"key":"B26","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1161\/CIRCULATIONAHA.124.072055","article-title":"Effects of the nonsteroidal MRA finerenone with and without concomitant SGLT2 inhibitor use in heart failure","volume":"151","author":"Vaduganathan","year":"2025","journal-title":"Circulation"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.jacc.2023.03.393","article-title":"2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology solution set oversight committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1161\/CIRCULATIONAHA.118.034646","article-title":"A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction","volume":"138","author":"Reddy","year":"2018","journal-title":"Circulation"},{"key":"B29","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the heart failure association (HFA) of the European Society of Cardiology (ESC)","volume":"40","author":"Pieske","year":"2019","journal-title":"Eur Heart J"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"ATTR-ACT Study investigators. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.jchf.2015.10.007","article-title":"Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction","volume":"4","author":"Franssen","year":"2016","journal-title":"JACC Heart Fail"},{"key":"B33","doi-asserted-by":"publisher","first-page":"sfae346","DOI":"10.1093\/ckj\/sfae346","article-title":"Clinical implications of mineralocorticoid receptor overactivation","volume":"18","author":"El Mouhayyar","year":"2024","journal-title":"Clin Kidney J"},{"key":"B34","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00395-020-0798-y","article-title":"Microvascular and lymphatic dysfunction in HFpEF and its associated comorbidities","volume":"115","author":"Cuijpers","year":"2020","journal-title":"Basic Res Cardiol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1161\/CIRCULATIONAHA.114.013215","article-title":"Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin","volume":"131","author":"Zile","year":"2015","journal-title":"Circulation"},{"key":"B36","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41569-020-00480-6","article-title":"Cellular and molecular pathobiology of heart failure with preserved ejection fraction","volume":"18","author":"Mishra","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41569-019-0315-x","article-title":"Reappraising the role of inflammation in heart failure","volume":"17","author":"Adamo","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"B39","doi-asserted-by":"publisher","first-page":"101162","DOI":"10.1016\/j.ijcha.2022.101162","article-title":"Adiposity and clinical outcomes in east Asian patients with heart failure and preserved ejection fraction","volume":"44","author":"Seki","year":"2022","journal-title":"Int J Cardiol Heart Vasc"},{"key":"B40","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41569-018-0044-6","article-title":"Metabolic remodelling in heart failure","volume":"15","author":"Bertero","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"46","DOI":"10.14336\/AD.2022.0523","article-title":"The NO-cGMP-PKG axis in HFpEF: from pathological mechanisms to potential therapies","volume":"14","author":"Cai","year":"2023","journal-title":"Aging Dis"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1161\/CIRCRESAHA.121.318241","article-title":"Cardiac energy metabolism in heart failure","volume":"128","author":"Lopaschuk","year":"2021","journal-title":"Circ Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41586-019-1100-z","article-title":"Nitrosative stress drives heart failure with preserved ejection fraction","volume":"568","author":"Schiattarella","year":"2019","journal-title":"Nature"},{"key":"B44","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nature10992","article-title":"Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure","volume":"485","author":"Oka","year":"2012","journal-title":"Nature"},{"key":"B45","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1042\/BCJ20170714","article-title":"Mitochondrial DNA as an inflammatory mediator in cardiovascular diseases","volume":"475","author":"Nakayama","year":"2018","journal-title":"Biochem J"},{"key":"B46","doi-asserted-by":"publisher","first-page":"122185","DOI":"10.1016\/j.lfs.2023.122185","article-title":"NLRP3-inflammasome Inhibition by MCC950 attenuates cardiac and pulmonary artery remodelling in heart failure with preserved ejection fraction","volume":"333","author":"Cheng","year":"2023","journal-title":"Life Sci"},{"key":"B47","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1001\/jamacardio.2023.0957","article-title":"Skeletal muscle mitochondrial respiration and exercise intolerance in patients with heart failure with preserved ejection fraction","volume":"8","author":"Scandalis","year":"2023","journal-title":"JAMA Cardiol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.jchf.2016.03.011","article-title":"Skeletal muscle mitochondrial content, oxidative capacity, and Mfn2 expression are reduced in older patients with heart failure and preserved ejection fraction and are related to exercise intolerance","volume":"4","author":"Molina","year":"2016","journal-title":"JACC Heart Fail"},{"key":"B49","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ijcard.2016.07.135","article-title":"Sarcopenia in patients with heart failure with preserved ejection fraction: impact on muscle strength, exercise capacity and quality of life","volume":"222","author":"Bekfani","year":"2016","journal-title":"Int J Cardiol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"EMPEROR-Preserved Trial investigators. Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"B51","first-page":"1089","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume-title":"N Engl J Med","author":"Solomon","year":"2022"},{"key":"B52","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"B53","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"B58","year":""},{"key":"B59","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/nrcardio.2015.14","article-title":"The vulnerable phase after hospitalization for heart failure","volume":"12","author":"Greene","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1016\/j.jacc.2020.09.542","article-title":"Interpreting the Kansas city cardiomyopathy questionnaire in clinical trials and clinical care: JACC state-of-the-art review","volume":"76","author":"Spertus","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jchf.2021.01.014","article-title":"Worsening heart failure episodes outside a hospital setting in heart failure with preserved ejection fraction: the PARAGON-HF trial","volume":"9","author":"Vaduganathan","year":"2021","journal-title":"JACC Heart Fail"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1016\/j.jacc.2016.02.018","article-title":"Extracellular volume fraction for characterization of patients with heart failure and preserved ejection fraction","volume":"67","author":"Rommel","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1093\/eurheartj\/ehx721","article-title":"Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction","volume":"39","author":"Taqueti","year":"2018","journal-title":"Eur Heart J"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1161\/CIRCULATIONAHA.119.041886","article-title":"Research priorities for heart failure with preserved ejection fraction: national heart, lung, and blood institute working group summary","volume":"141","author":"Shah","year":"2020","journal-title":"Circulation"},{"key":"B65","doi-asserted-by":"publisher","first-page":"xuag153","DOI":"10.1093\/ejhf\/xuag153","article-title":"Ziltivekimab in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the ATHENA and HERMES trials","author":"Mendieta","year":"2026","journal-title":"Eur J Heart Fail"},{"key":"B66","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1001\/jamacardio.2024.4539","article-title":"Finerenone, Serum potassium, and clinical outcomes in heart failure with mildly reduced or preserved ejection fraction","volume":"10","author":"Vardeny","year":"2025","journal-title":"JAMA Cardiol"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1880045\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T05:39:38Z","timestamp":1781588378000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1880045\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":66,"alternative-id":["10.3389\/fcvm.2026.1880045"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1880045","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"article-number":"1880045"}}